128 related articles for article (PubMed ID: 9450575)
1. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo.
Applebaum J; Reynolds S; Knispel J; Oratz R; Shapiro R; Bystryn JC
J Natl Cancer Inst; 1998 Jan; 90(2):146-9. PubMed ID: 9450575
[TBL] [Abstract][Full Text] [Related]
2. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Bystryn JC; Henn M; Li J; Shroba S
Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848
[TBL] [Abstract][Full Text] [Related]
3. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine.
Miller K; Abeles G; Oratz R; Zeleniuch-Jacquotte A; Cui J; Roses DF; Harris MN; Bystryn JC
Cancer; 1995 Jan; 75(2):495-502. PubMed ID: 7812920
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of a polyvalent melanoma antigen vaccine.
Bystryn JC
Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice.
Johnston D; Bystryn JC
Cancer Immunol Immunother; 2005 Apr; 54(4):345-50. PubMed ID: 15692845
[TBL] [Abstract][Full Text] [Related]
6. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
8. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
9. MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis.
Dubovsky JA; Albertini MR; McNeel DG
J Immunother; 2007 Oct; 30(7):675-83. PubMed ID: 17893560
[TBL] [Abstract][Full Text] [Related]
10. Identification of immunogenic B16 melanoma-associated antigens.
Johnston D; Schachne JP; Bystryn JC
J Biol Response Mod; 1987 Apr; 6(2):108-20. PubMed ID: 3585408
[TBL] [Abstract][Full Text] [Related]
11. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells.
Livingston PO; Takeyama H; Pollack MS; Houghton AN; Albino A; Pinsky CM; Oettgen HF; Old LJ
Int J Cancer; 1983 May; 31(5):567-75. PubMed ID: 6852975
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.
Ehlken H; Schadendorf D; Eichmüller S
Int J Cancer; 2004 Jan; 108(2):307-13. PubMed ID: 14639620
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
16. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
17. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
[TBL] [Abstract][Full Text] [Related]
18. Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics.
Shiku H; Takahashi T; Resnick LA; Oettgen HF; Old LJ
J Exp Med; 1977 Mar; 145(3):784-9. PubMed ID: 233917
[TBL] [Abstract][Full Text] [Related]
19. Immunity to melanoma associated antigens detected by both leukocyte adherence inhibition and antibody dependent cellular cytotoxicity assays.
Plain MJ; Whitehead RH; Jose DG
Pathology; 1983 Apr; 15(2):177-82. PubMed ID: 6888965
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
